BioSpace News Archive

Medigene AG will present a poster at the American Association for Cancer Research Virtual Annual Meeting 2023 being held on April 14-19, 2023.

Coave Therapeutics announces that CEO Rodolphe Clerval will provide a company overview at the following conferences.

Isologic Innovative Radiopharmaceuticals is proud to announce that the prostate cancer imaging agent Illuccix®, Ga 68 Gozetotide Preparation Kit, also known as PSMA-11, is now available in Canada.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

OKYO Pharma Limited announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website.

Embolx, Inc. announced the signing of a distribution agreement with Cardiva Italia SRL.

Anaveon announced the first patient dosed with ANV419 in the OMNIA-2 study - a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone.

Evotec SE announced progress within the Company’s strategic partnership with Bristol Myers Squibb relating to building a molecular glue-based pipeline.

Biovica International DiviTum® TKa ready for clinical use in the US

Modra Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane therapeutic ModraDoc006/r. ModraDoc006/r is an oral tablet formulation of docetaxel co-administered with ritonavir, a boosting agent that enhances bioavailability.